Phase II Trial Testing the PARP Inhibitor Niraparib in Patients With Pancreatic Cancer Harboring Deficiencies in Homologous Recombination DNA Repair
Summary
The purpose of this phase II research study is to evaluate the efficacy of niraparib as a possible treatment for pancreatic cancer.
General Information
NCT#: NCT03601923
Study ID: 18-207
Trial Phase: Phase II
Trial Sponsor: Dana-Farber Cancer Institute, Tesaro
Therapies Used in This Trial: Niraparib